Use access key #2 to skip to page content.

Melaschasm (57.22)

By the Numbers: NVO

Recs

1

March 18, 2010 – Comments (0) | RELATED TICKERS: NVO

NVO - Novo Nordisk A/S  - Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.

Some CAPS Information

5 Star Rating

Total Debt-to-Equity Ratio = 0.03

Return on Equity (TTM) = 29.40

Price-to-Earnings (TTM) = 22.70

Price-to-Book (TTM) = 7.05

Do you think this is a great buy, or is this stock going to underperform for the next few years? 

0 Comments – Post Your Own

Featured Broker Partners


Advertisement